These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical and prognostic role of annexin A2 in multiple myeloma. Seckinger A; Meissner T; Moreaux J; Depeweg D; Hillengass J; Hose K; Rème T; Rösen-Wolff A; Jauch A; Schnettler R; Ewerbeck V; Goldschmidt H; Klein B; Hose D Blood; 2012 Aug; 120(5):1087-94. PubMed ID: 22705595 [TBL] [Abstract][Full Text] [Related]
5. An atlas of the bone marrow bone proteome in patients with dysproteinemias. Ho M; Dasari S; Visram A; Drake MT; Charlesworth MC; Johnson KL; Pujari GP; Jevremovic D; Kourelis T Blood Cancer J; 2023 Apr; 13(1):63. PubMed ID: 37105956 [TBL] [Abstract][Full Text] [Related]
6. BM-MSCs-derived ECM modifies multiple myeloma phenotype and drug response in a source-dependent manner. Ibraheem A; Attar-Schneider O; Dabbah M; Dolberg Jarchowsky O; Tartakover Matalon S; Lishner M; Drucker L Transl Res; 2019 May; 207():83-95. PubMed ID: 30738861 [TBL] [Abstract][Full Text] [Related]
7. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. Wang W; Corrigan-Cummins M; Barber EA; Saleh LM; Zingone A; Ghafoor A; Costello R; Zhang Y; Kurlander RJ; Korde N; Roccaro AM; Ghobrial IM; Landgren O; Calvo KR J Mol Diagn; 2015 Nov; 17(6):669-78. PubMed ID: 26433312 [TBL] [Abstract][Full Text] [Related]
8. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. D'Souza S; Kurihara N; Shiozawa Y; Joseph J; Taichman R; Galson DL; Roodman GD Blood; 2012 Feb; 119(8):1888-96. PubMed ID: 22223826 [TBL] [Abstract][Full Text] [Related]
9. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422 [TBL] [Abstract][Full Text] [Related]
10. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis. Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275 [TBL] [Abstract][Full Text] [Related]
11. Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis. Gámez B; Edwards CM Curr Osteoporos Rep; 2018 Dec; 16(6):635-641. PubMed ID: 30229522 [TBL] [Abstract][Full Text] [Related]
12. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes. Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841 [TBL] [Abstract][Full Text] [Related]
13. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma. Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273 [TBL] [Abstract][Full Text] [Related]
14. Extracellular matrix in bone marrow can mediate drug resistance in myeloma. Vincent T; Mechti N Leuk Lymphoma; 2005 Jun; 46(6):803-11. PubMed ID: 16019524 [TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957 [TBL] [Abstract][Full Text] [Related]
16. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Azab AK; Quang P; Azab F; Pitsillides C; Thompson B; Chonghaile T; Patton JT; Maiso P; Monrose V; Sacco A; Ngo HT; Flores LM; Lin CP; Magnani JL; Kung AL; Letai A; Carrasco R; Roccaro AM; Ghobrial IM Blood; 2012 Feb; 119(6):1468-78. PubMed ID: 22096244 [TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma in the marrow: pathogenesis and treatments. Fairfield H; Falank C; Avery L; Reagan MR Ann N Y Acad Sci; 2016 Jan; 1364(1):32-51. PubMed ID: 27002787 [TBL] [Abstract][Full Text] [Related]
18. Characterization of bone marrow stromal cells from multiple myeloma. Gregoretti MG; Gottardi D; Ghia P; Bergui L; Merico F; Marchisio PC; Caligaris-Cappio F Leuk Res; 1994 Sep; 18(9):675-82. PubMed ID: 7934143 [TBL] [Abstract][Full Text] [Related]
19. Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study. Huang SY; Lin HH; Yao M; Tang JL; Wu SJ; Hou HA; Chou WC; Chou SC; Hsu SC; Ko BS; Lu HY; Tsay W; Tien HF PLoS One; 2015; 10(9):e0137552. PubMed ID: 26379028 [TBL] [Abstract][Full Text] [Related]
20. Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Balakumaran A; Robey PG; Fedarko N; Landgren O Expert Rev Mol Diagn; 2010 May; 10(4):465-80. PubMed ID: 20465501 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]